These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 20605846)

  • 1. Newer antibacterial agents and their potential role in cystic fibrosis pulmonary exacerbation management.
    Parkins MD; Elborn JS
    J Antimicrob Chemother; 2010 Sep; 65(9):1853-61. PubMed ID: 20605846
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro activity of β-lactams in combination with avibactam against multidrug-resistant Pseudomonas aeruginosa, Stenotrophomonas maltophilia and Achromobacter xylosoxidans isolates from patients with cystic fibrosis.
    Mathy V; Grohs P; Compain F
    J Med Microbiol; 2018 Sep; 67(9):1217-1220. PubMed ID: 30016231
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pan-Resistant Achromobacter xylosoxidans and Stenotrophomonas maltophilia Infection in Cystic Fibrosis Does Not Reduce Survival After Lung Transplantation.
    Lobo LJ; Tulu Z; Aris RM; Noone PG
    Transplantation; 2015 Oct; 99(10):2196-202. PubMed ID: 25856407
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Seasonality of acquisition of respiratory bacterial pathogens in young children with cystic fibrosis.
    Psoter KJ; De Roos AJ; Wakefield J; Mayer JD; Rosenfeld M
    BMC Infect Dis; 2017 Jun; 17(1):411. PubMed ID: 28599639
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro antimicrobial activity of ceftolozane/tazobactam against Pseudomonas aeruginosa and other non-fermenting Gram-negative bacteria in adults with cystic fibrosis.
    Gramegna A; Millar BC; Blasi F; Elborn JS; Downey DG; Moore JE
    J Glob Antimicrob Resist; 2018 Sep; 14():224-227. PubMed ID: 29559421
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increasing Incidence of Multidrug Resistance Among Cystic Fibrosis Respiratory Bacterial Isolates.
    Rutter WC; Burgess DR; Burgess DS
    Microb Drug Resist; 2017 Jan; 23(1):51-55. PubMed ID: 27326758
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pitfalls of polymyxin antimicrobial susceptibility testing of Pseudomonas aeruginosa isolated from cystic fibrosis patients.
    Hogardt M; Schmoldt S; Götzfried M; Adler K; Heesemann J
    J Antimicrob Chemother; 2004 Dec; 54(6):1057-61. PubMed ID: 15509615
    [TBL] [Abstract][Full Text] [Related]  

  • 8. What's new and not so new on the antimicrobial horizon?
    French GL
    Clin Microbiol Infect; 2008 Dec; 14 Suppl 6():19-29. PubMed ID: 19040463
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Does Cefiderocol Have a Potential Role in Cystic Fibrosis Pulmonary Exacerbation Management?
    Gavioli EM; Guardado N; Haniff F; Deiab N; Vider E
    Microb Drug Resist; 2021 Dec; 27(12):1726-1732. PubMed ID: 34077286
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antibacterial potential of
    Crisan CV; Pettis ML; Goldberg JB
    mSphere; 2024 Jul; 9(7):e0033524. PubMed ID: 38980073
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Emerging and unusual gram-negative infections in cystic fibrosis.
    Davies JC; Rubin BK
    Semin Respir Crit Care Med; 2007 Jun; 28(3):312-21. PubMed ID: 17562501
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antibacterial drug discovery and development--SRI's 11th Annual Summit.
    Hawser SP
    IDrugs; 2006 Jun; 9(6):390-3. PubMed ID: 16752304
    [No Abstract]   [Full Text] [Related]  

  • 13. Inflammation in Achromobacter xylosoxidans infected cystic fibrosis patients.
    Hansen CR; Pressler T; Nielsen KG; Jensen PØ; Bjarnsholt T; Høiby N
    J Cyst Fibros; 2010 Jan; 9(1):51-8. PubMed ID: 19939747
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Minocycline--an old drug for a new century: emphasis on methicillin-resistant Staphylococcus aureus (MRSA) and Acinetobacter baumannii.
    Bishburg E; Bishburg K
    Int J Antimicrob Agents; 2009 Nov; 34(5):395-401. PubMed ID: 19665876
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New antibiotics for healthcare-associated pneumonia.
    Neuner EA; Ritchie DJ; Micek ST
    Semin Respir Crit Care Med; 2009 Feb; 30(1):92-101. PubMed ID: 19199191
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: VI. Executive summary.
    Zobell JT; Young DC; Waters CD; Ampofo K; Stockmann C; Sherwin CM; Spigarelli MG
    Pediatr Pulmonol; 2013 Jun; 48(6):525-37. PubMed ID: 23359557
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ceftobiprole: a novel cephalosporin with activity against Gram-positive and Gram-negative pathogens, including methicillin-resistant Staphylococcus aureus (MRSA).
    Barbour A; Schmidt S; Rand KH; Derendorf H
    Int J Antimicrob Agents; 2009 Jul; 34(1):1-7. PubMed ID: 19261449
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro activity of ceftobiprole, linezolid, tigecycline, and 23 other antimicrobial agents against Staphylococcus aureus isolates in China.
    Wang H; Liu Y; Sun H; Xu Y; Xie X; Chen M
    Diagn Microbiol Infect Dis; 2008 Oct; 62(2):226-9. PubMed ID: 18653301
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical profile of adult cystic fibrosis patients with frequent epidemic clones of Pseudomonas aeruginosa.
    Tingpej P; Elkins M; Rose B; Hu H; Moriarty C; Manos J; Barras B; Bye P; Harbour C
    Respirology; 2010 Aug; 15(6):923-9. PubMed ID: 20573059
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antimicrobial susceptibility profile of molecular typed cystic fibrosis Stenotrophomonas maltophilia isolates and differences with noncystic fibrosis isolates.
    Cantón R; Valdezate S; Vindel A; Sánchez Del Saz B; Maíz L; Baquero F
    Pediatr Pulmonol; 2003 Feb; 35(2):99-107. PubMed ID: 12526070
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.